Key result
Dexmedetomidine sedation during PSVT ablation did not alter arrhythmia inducibility compared to fentanyl and midazolam.
Why the study?
Does dexmedetomidine sedation reduce PSVT inducibility in patients undergoing PSVT ablation?
Cohort (n=326)
Does dexmedetomidine sedation reduce PSVT inducibility in patients undergoing PSVT ablation?
Dexmedetomidine provides predictable sedation during PSVT ablation without altering arrhythmia inducibility, though it is associated with increased intraprocedural hypotension.
Answers are grounded in this paper and cite their sources.
Supports dexmedetomidine as sedation option for PSVT ablation; cohort data leaves open randomized confirmation.
BACKGROUND: Dexmedetomidine (Dex) is an attractive agent for procedural sedation due to its unique pharmacodynamic profile, specifically affording predictable sedation without concurrent respiratory depression. However, Dex has previously been reported to prevent or terminate arrhythmias. The purpose of this study was to investigate paroxysmal supraventricular tachycardia (PSVT) inducibility and homeostatic stability during electrophysiology studies (EPSs) and ablation when a standardized Dex protocol was used as the primary sedation agent. METHODS: We performed a retrospective review of 163 consecutive procedures for PSVT ablation that received Dex as the primary sedative with adjunct fentanyl and midazolam boluses (DEX-FENT-MIDAZ). This cohort was compared to 163 consecutive control procedures wherein strictly fentanyl and midazolam were used for sedation. The primary outcome reviewed was PSVT inducibility assessed before ablation. Reviewed secondary outcomes included level of sedation and intraprocedure hemodynamics and oxygenation. RESULTS: The arrhythmia profiles of the DEX-FENT-MIDAZ and control cohorts were very similar. The overall incidence of a "negative" EPSs in which arrhythmia was not induced was 24% in the DEX-FENT-MIDAZ group and 26% in the control group (P = .7). Unintended deep sedation was significantly less with DEX-FENT-MIDAZ (4.3% vs 27%; P ≤ .0001). However, DEX-FENT-MIDAZ use was associated with a higher incidence of intraprocedure hypotension. CONCLUSIONS: Dex sedation during EPSs is not associated with a reduction in PSVT inducibility. The therapeutic utility of Dex during EPS arises from the predictable sedation Dex affords but is associated with an increased incidence of intraprocedure hypotension.
No takes yet. Share an insight, caveat, or question.
Slupe et al. (2018) conducted a cohort in Paroxysmal supraventricular tachycardia (PSVT) (n=326). Dexmedetomidine with adjunct fentanyl and midazolam vs. Fentanyl and midazolam was evaluated on PSVT inducibility assessed before ablation (negative EPSs) (p=.7). Dexmedetomidine sedation during PSVT ablation did not alter arrhythmia inducibility compared to fentanyl and midazolam.
Synapse has enriched 10 related papers. Consider them for comparative context: